Source: International Congress 2017 – Late-breaking findings in pulmonary diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Kouchakji (San Francisco, United States of America), M. Lanclus. Late Breaking Abstract - Responder phenotyping using functional respiratory imaging (FRI) in IPF patients treated with anti-CGTG monoclonal antibody FG3019. 2811

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract - Prevalence and clinical significance of antinuclear antibody (ANA) in IPF: analysis from ESTAIR study Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019 Late Breaking Abstract - Assessment of disease progression in IPF patients using Functional Respiratory Imaging (FRI) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems Year: 2017 Late Breaking Abstract - The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients. Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract - Change in airway volume, measured with functional respiratory imaging (FRI), differentiates between stable and progressive idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Late Breaking Abstract - Functional respiratory imaging (FRI) and lung function assessment of glycopyrronium/formoterol fumarate dihydrate fixed-dose combination delivered using novel Co-Suspension Delivery Technology (GFF MDI) in COPD Source: International Congress 2017 – Novel studies on bronchodilators and cough Year: 2017 Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Late Breaking Abstract - Tocilizumab (T) plus pembrolizumab (P) in patients (pts) with Covid-19 pneumonia: COPERNICO Source: Virtual Congress 2021 – COVID-19 acute respiratory distress syndrome Year: 2021 Late Breaking Abstract - Detection of clinical instability by eNose in COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Late Breaking Abstract: Novel detection of exacerbations of COPD with patient reported outcome (EXACT-PRO) and Blackberry (BB) Source: Annual Congress 2010 - Asthma and COPD: understanding through monitoring Year: 2010 Late Breaking Abstract - ENose based phenotyping of newly presented patients with asthma or COPD Source: International Congress 2018 – Biomarkers in COPD and asthma Year: 2018 Change of T2-markers in patients with severe uncontrolled asthma treated by monoclonal antibodies: 1 yr follow up Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 Late Breaking Abstract - Comparison of clinical characteristics between severe adult asthmatics in Brazil(ProAR) and Europe(U-BIOPRED). Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - Compare outcomes between COPD patients treated with tiotropium/olodaterol (TIO/OLO) and umeclidium/vilanterol (UMEC/VI) Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 Late Breaking Abstract - Lung deposition of two different ICS/LABA combinations with Dry Powder Inhaler (DPI) in asthmatic patients using Functional Respiratory Imaging (FRI). Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update Year: 2019 Late Breaking Abstract - Clinical utility of basophil activating test (BAT) in subjects with drug-induced lung disease. Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management Year: 2018 Long-term treatment with monoclonal antibodies anti-IgE in severe asthma: Follow-up of ten patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011